Natco Pharma signs voluntary licensing agreement with Lilly for Baricitinib for Covid-19 in India

17 May 2021 Evaluate

Natco Pharma has signed a royalty-free, non-exclusive, voluntary licensing agreement with Eli Lilly and Company, for the manufacture and commercialization of the drug Baricitinib for Covid-19 indication in India. In line with the licensing agreement, Natco has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for Covid-19 in India. 

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

891.50 -12.05 (-1.33%)
01-Jan-2026 09:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1711.05
Dr. Reddys Lab 1253.70
Cipla 1502.90
Zydus Lifesciences 909.80
Lupin 2088.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×